Markus Muehlhan

Markus Muehlhan

Auto-generated profile, based on publicly available information

Markus Muehlhan

Department of Psychology, Faculty of Human Sciences, Medical School Hamburg, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2011 in International Journal of Psychophysiology
Verified
Journal Article
Closed access
MMMarkus Muehlhan
Markus Muehlhan
ULUlrike Lueken
Ulrike Lueken
HWHans-Ulrich Wittchen
Hans-Ulrich Wittchen
CKClemens Kirschbaum
Clemens Kirschbaum

17 August 2010 in Human Brain Mapping
Verified
Journal Article
Closed access
RWRiklef Weerda
Riklef Weerda
MMMarkus Muehlhan
Markus Muehlhan
OWOliver T. Wolf
Oliver T. Wolf
CTChristiane M. Thiel
Christiane M. Thiel


1 May 2011 in NeuroImage
Verified
Journal Article
Closed access
ULUlrike Lueken
Ulrike Lueken
JKJohann Daniel Kruschwitz
Johann Daniel Kruschwitz
MMMarkus Muehlhan
Markus Muehlhan
JSJens Siegert
Jens Siegert
JHJürgen Hoyer
Jürgen Hoyer
HWHans-Ulrich Wittchen
Hans-Ulrich Wittchen

12 February 2017 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
KHKevin Hilbert
Kevin Hilbert
ULUlrike Lueken
Ulrike Lueken
MMMarkus Muehlhan
Markus Muehlhan
KBKatja Beesdo‐Baum
Katja Beesdo‐Baum
Background: Generalized anxiety disorder (GAD) is difficult to recognize and hard to separate from major depression (MD) in clinical settings. Biomarkers might support diagnostic decisions. This study used machine learning on multimodal biobehavioral data from a sample of GAD, MD and healthy subjects to differentiate subjects with a disorder from healthy subjects (case‐classification) and to differentiate GAD from MD (disorder‐classification).Methods: Subjects with GAD (n = 19), MD without GAD (n = 14), and healthy comparison subjects (n = 24) were included. The sample was matched regarding age, sex, handedness and education and free of psychopharmacological medication. Binary support vector machines were used within a nested leave‐one‐out cross‐validation framework. Clinical questionnaires, cortisol release, gray matter (GM), and white matter (WM) volumes were used as input data separately and in combination.Results: Questionnaire data were well‐suited for case‐classification but not disorder‐classification (accuracies: 96.40%, p < .001; 56.58%, p > .22). The opposite pattern was found for imaging data (case‐classification GM/WM: 58.71%, p = .09/43.18%, p > .66; disorder‐classification GM/WM: 68.05%, p = .034/58.27%, p > .15) and for cortisol data (38.02%, p = .84; 74.60%, p = .009). All data combined achieved 90.10% accuracy (p < .001) for case‐classification and 67.46% accuracy (p = .0268) for disorder‐classification.Conclusions: In line with previous evidence, classification of GAD was difficult using clinical questionnaire data alone. Particularly cortisol and GM volume data were able to provide incremental value for the classification of GAD. Findings suggest that neurobiological biomarkers are a useful target for further research to delineate their potential contribution to diagnostic processes.

1 April 2018 in Psychoneuroendocrinology
Verified
Journal Article
Closed access
NANina Alexander
Nina Alexander
CKClemens Kirschbaum
Clemens Kirschbaum
MWMatthis Wankerl
Matthis Wankerl
BSBenjamin J. Stauch
Benjamin J. Stauch
TSTobias Stalder
Tobias Stalder
RMRobert Miller
Robert Miller